Emicizumab Data Has Shire And Novo Looking Over Their Shoulders
Positive data from the HAVEN 1 Phase III study of Genentech's emicizumab put pressure on the hemophilia franchises of both Shire and Novo Nordisk.
Positive data from the HAVEN 1 Phase III study of Genentech's emicizumab put pressure on the hemophilia franchises of both Shire and Novo Nordisk.